News | January 24, 2025
Syngene reports 18% jump in Q3 FY25 PAT at Rs. 131 Cr
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
Eculizumab is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome
The conference featured comprehensive discussions, field visits, and knowledge-sharing sessions addressing different aspect of major NCDs
The certification marks a new chapter in Windlas Biotech’s growth trajectory,
Data from IDSP does not indicate any unusual rise in ILI/SARI cases anywhere in the country
40th DSIR Foundation Day celebration marks 16 more technology transfers from CSIR to MSMEs
2.92 acre facility will combine tradition and innovation, offering new opportunities for holistic healing, specialized clinics, and skill development to be constructed at a cost of around Rs. 185 crore
Inaugurates new facilities to further NIMHANS’ mission of delivering cutting-edge care in mental health and neurosciences
Subscribe To Our Newsletter & Stay Updated
